Meeting ReportOncology, Clinical Diagnosis Track
High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial
Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Sue Ping Thang, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 531;
Michael Hofman
1Centre for Molecular Imaging Peter MacCalllum Cancer Centre Melbourne VIC Australia
John Violet
3Radiation Oncology Peter MacCalllum Cancer Centre Melbourne VIC Australia
Shahneen Sandhu
2Medical Oncology Peter MacCalllum Cancer Centre Melbourne VIC Australia
Justin Ferdinandus
1Centre for Molecular Imaging Peter MacCalllum Cancer Centre Melbourne VIC Australia
Sue Ping Thang
6Department of Nuclear Medicine and PET Singapore General Hospital Singapore Singapore
Amir Iravani
1Centre for Molecular Imaging Peter MacCalllum Cancer Centre Melbourne VIC Australia
Grace Kong
1Centre for Molecular Imaging Peter MacCalllum Cancer Centre Melbourne VIC Australia
Aravind Ravi Kumar
1Centre for Molecular Imaging Peter MacCalllum Cancer Centre Melbourne VIC Australia
Tim Akhurst
1Centre for Molecular Imaging Peter MacCalllum Cancer Centre Melbourne VIC Australia
Price Jackson
5Medical Physics Peter MacCallum Cancer Centre Melbourne Australia
Mark Scalzo
1Centre for Molecular Imaging Peter MacCalllum Cancer Centre Melbourne VIC Australia
Scott Williams
3Radiation Oncology Peter MacCalllum Cancer Centre Melbourne VIC Australia
Rodney Hicks
4Centre for Molecular Imaging Peter MacCallum Cancer Centre Melbourne VIC Australia
In this issue
Journal of Nuclear Medicine
Vol. 59, Issue supplement 1
May 1, 2018
High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial
Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Sue Ping Thang, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Price Jackson, Mark Scalzo, Scott Williams, Rodney Hicks
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 531;
High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial
Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Sue Ping Thang, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Price Jackson, Mark Scalzo, Scott Williams, Rodney Hicks
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 531;
Jump to section
Related Articles
- No related articles found.